PsoriasisNCT07494396
An AI-Based Erythema Measurement System for Psoriasis Lesions
An observational study of Psoriasis, run by Khon Kaen University at 1 site in Thailand.
Trial summary
Psoriasis is a common chronic inflammatory skin disease. Disease severity is commonly assessed using the Psoriasis Area and Severity Index (PASI), in which erythema is graded subjectively on a 0-4 scale. This visual assessment is prone to significant inter- and intra-rater variability. Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Psoriasis
- How many people
- 50 participants
- Where
- 1 siteThailand
- Study dates
- 1 Nov 2026to 20 Apr 2027
- How long will I take part?
- 12 Weeks
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: A dermatology clinic in Srinagarind Hospital
Who may be able to join
- Adults aged ≥18 years
- Diagnosed with psoriasis by a dermatologist
- Presence of at least five clearly photographable lesions
- Willing and able to take photographs using a smartphone with both a standard color calibration card and a study-specific color card at home weekly, and submit images via Line or email
- Willing to have clinical photographs taken at baseline and at a follow-up visit
- Provides written informed consent to participate in the study
Who cannot join
- Presence of skin infection or other lesions that may interfere with color assessment (e.g., tattoos)
- Use of self-tanning products or substances that alter skin color
- Inability to perform photography or comply with study procedures
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Thailand1 site
Khon Kaen University
Khon Kaen, Changwat Khon Kaen, 40002
Suteeraporn Chaowattanapanit, +66891879719, csuteeraporn@yahoo.com
About this study
Official title: Development and Validation of an AI-Based Erythema Measurement System for Psoriasis Lesions Using Smartphone Imaging With Color Card Compared to Standard Color Calibration Device
Psoriasis is a common chronic inflammatory skin disease. Disease severity is commonly assessed using the Psoriasis Area and Severity Index (PASI), in which erythema is graded subjectively on a 0-4 scale. This visual assessment is prone to significant inter- and intra-rater variability.
Although objective tools such as colorimeters provide accurate erythema measurement, their high cost limits routine clinical use. Smartphone imaging combined with artificial intelligence (AI) offers a practical alternative for objective assessment. However, variability in lighting conditions can affect image consistency. Incorporating a color calibration card enables accurate color normalization.
This study aims to develop and validate an AI-based system for measuring erythema in psoriatic lesions using smartphone images with a color card, compared against a standard colorimeter to assess validity and reliability.
- Conditions
- Psoriasis
- Being tested
- No additional drugs(control Group)
- Medical subject headings
- Psoriasis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No additional drugs(control Group)Diagnostic test
This study is distinct from other clinical studies in that it does not involve any therapeutic intervention or modification of standard patient care. Instead, it evaluates a non-invasive, image-based measurement system that combines smartphone photography, a color calibration card, and artificial intelligence to quantify erythema in psoriasis lesions. Unlike conventional approaches that rely on subjective physician scoring or require specialized and costly equipment, this intervention is designed to be low-cost, accessible, and applicable in real-world settings, including patient self-monitoring at home.
What is being measured
The primary outcome is the main question the study is designed to answer.
To evaluate the accuracy of erythema measurements of psoriatic lesions obtained from an AI-based erythema model (smartphone imaging with a color calibration card) compared with a standard color calibration device (gold standard).
Measured: From enrollment to 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Mar 2026
- Study start1 Nov 2026 (estimated)
- Primary completion20 Apr 2027 (estimated)
- Study completion20 Apr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PsoriasisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 50 participants (estimated)
- Target duration
- 12 Weeks
Sponsor and investigators
- Lead sponsor
- Khon Kaen University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Suteeraporn Chaowattanapanit, Khon Kaen University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07494396
- Sponsor's protocol ID
- HE694001
- Status last verified
- Aug 2026
- First submitted
- 20 Mar 2026
- Last updated
- 5 Aug 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Development and Validation of an AI-Based Erythema Measurement System for Psoriasis Lesions Using Smartphone Imaging With Color Card Compared to Standard Color Calibration Device
- ClinicalTrials.gov ID
- NCT07494396
- Acronym / sponsor ID
- HE694001
- Conditions
- Psoriasis
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Khon Kaen UniversityUniversity, hospital or other
- Study start
- 1 Nov 2026 (estimated)
- Primary completion
- 20 Apr 2027 (estimated)
- Study completion
- 20 Apr 2027 (estimated)
- First posted
- 27 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Psoriasis is a common chronic inflammatory skin disease. Disease severity is commonly assessed using the Psoriasis Area and Severity Index (PASI), in which erythema is graded subjectively on a 0-4 scale. This visual assessment is prone to significant inter- and intra-rater variability.
Although objective tools such as colorimeters provide accurate erythema measurement, their high cost limits routine clinical use. Smartphone imaging combined with artificial intelligence (AI) offers a practical alternative for objective assessment. However, variability in lighting conditions can affect image consistency. Incorporating a color calibration card enables accurate color normalization.
This study aims to develop and validate an AI-based system for measuring erythema in psoriatic lesions using smartphone images with a color card, compared against a standard colorimeter to assess validity and reliability.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Target follow-up
- 12 Weeks
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- A dermatology clinic in Srinagarind Hospital
Key inclusion criteria (6 listed)
- Adults aged ≥18 years
- Diagnosed with psoriasis by a dermatologist
- Presence of at least five clearly photographable lesions
- Willing and able to take photographs using a smartphone with both a standard color calibration card and a study-specific color card at home weekly, and submit images via Line or email
- Willing to have clinical photographs taken at baseline and at a follow-up visit
Key exclusion criteria (3 listed)
- Presence of skin infection or other lesions that may interfere with color assessment (e.g., tattoos)
- Use of self-tanning products or substances that alter skin color
- Inability to perform photography or comply with study procedures
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No additional drugs(control Group)This study is distinct from other clinical studies in that it does not involve any therapeutic intervention or modification of standard patient care. Instead, it evaluates a non-invasive, image-based measurement system that combines smartphone photography, a color calibration card, and artificial intelligence to quantify erythema in psoriasis lesions. Unlike conventional approaches that rely on subjective physician scoring or require specialized and costly equipment, this intervention is designed to be low-cost, accessible, and applicable in real-world settings, including patient self-monitoring at home. | Diagnostic test | – |
Primary outcome
To evaluate the accuracy of erythema measurements of psoriatic lesions obtained from an AI-based erythema model (smartphone imaging with a color calibration card) compared with a standard color calibration device (gold standard).
Time frame: From enrollment to 12 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Psoriasis
Not yet recruitingPhase 2
Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)
Moderate to Severe Psoriatic Arthritis
Recruiting
Efficacy of a Self-Management Smartphone App to Improve Safety Skills in Patients With Inflammatory Arthritis
Rhumatoid Arthisis, Spondyloarthritis (SA)
Active, not recruitingPhase 2
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
Plaque Psoriasis
RecruitingPhase 1
A Study of HB0017 Injection in Healthy Volunteers to Evaluate Safety and Tolerability of a Single Subcutaneous Injection in Low-Body-Weight Subjects; and Pharmacokinetics at Different Subcutaneous Injection Sites at the Same Dose
Psoriasis, Ankylosing Spondylitis
RecruitingPhase 1
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
Psoriatic Arthritis, Axial Spondyloarthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Psoriasis, run by Khon Kaen University at 1 site in Thailand.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 5 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Thailand. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Suteeraporn Chaowattanapanit (+66891879719, csuteeraporn@yahoo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To evaluate the accuracy of erythema measurements of psoriatic lesions obtained from an AI-based erythema model (smartphone imaging with a color calibration card) compared with a standard color calibration device (gold standard). (time frame: From enrollment to 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Aug 2026.